EVAX (Evaxion AS) 3-Year RORE % : -60.98% (As of Mar. 2026)


EVAX Evaxion AS EVAX
22 GF Score
Price $3.43
! 2 Warning Signs
View Full Analysis

What is Evaxion AS 3-Year RORE %?

Evaxion AS EVAX +5.25% 22 3-Year RORE % is -60.98 as of Mar. 2026. GuruFocus rates EVAX with a GF Score™ of 22/100. The stock has 2 warning signs investors should review. Among 1,293 Biotechnology companies, Evaxion AS ranks worse than 86.08% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Evaxion AS's 3-Year RORE % for the quarter that ended in Mar. 2026 was -60.98%.

The industry rank for Evaxion AS's 3-Year RORE % or its related term are showing as below:

EVAX's 3-Year RORE % is ranked worse than
86.08% of 1293 companies
in the Biotechnology industry
Industry Median: -11.55 vs EVAX: -60.98

Evaxion AS  (NAS:EVAX) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Evaxion AS 3-Year RORE % Related Terms


Evaxion AS 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Evaxion AS's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evaxion AS 3-Year RORE % Chart

Evaxion AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only 0.00 3.81 -14.47 -39.20 -73.33

Evaxion AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -41.71 -53.50 -65.15 -73.33 -60.98

EVAX vs SER, NRSN, IGC: 3-Year RORE % Comparison

For the Biotechnology subindustry, Evaxion AS's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evaxion AS 3-Year RORE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evaxion AS's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Evaxion AS's 3-Year RORE % falls into.


EVAX
22GF Score
Evaxion AS EVAX
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evaxion AS 3-Year RORE % Calculation

Evaxion AS's 3-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -2--27 )/( -41-0 )
=25/-41
=-60.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -60.98 mean?
Evaxion AS (EVAX) has a 3-Year RORE % of -60.98 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Evaxion AS and its competitors. According to the industry distribution chart, Evaxion AS ranks #1113 out of 1293 companies in the Biotechnology industry, placing it in the top 86.1%.
Is Evaxion AS's 3-Year RORE % too high?
Evaxion AS's current 3-Year RORE % is -60.98. Based on the distribution chart, Evaxion AS ranks #1113 out of 1293 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Evaxion AS has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Evaxion AS's 3-Year RORE % compare to SER and NRSN?
According to the Biotechnology industry distribution chart, Evaxion AS ranks #1113 out of 1293 companies for 3-Year RORE %. This places Evaxion AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Evaxion AS and its competitors. Evaxion AS's current 3-Year RORE % is -60.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evaxion AS stock overvalued right now?
Evaxion AS (EVAX) has a current 3-Year RORE % of -60.98. The current 3-Year RORE % is -60.98. Evaxion AS's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Evaxion AS (EVAX), the current 3-Year RORE % is -60.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evaxion AS Business Description

Address Dr. Neergaards Vej 5f, Horsholm, DNK, 2970
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
22GF Score

Get the complete analysis for EVAX

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.43
Price